$MRNS
MARINUS PHARMACEUTICALS, INC.

2024 Q4 Form 10-Q Financial Statement

#000155837024015315 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $8.541M
YoY Change 16.39%
Cost Of Revenue $714.0K
YoY Change 55.22%
Gross Profit $7.827M
YoY Change 13.76%
Gross Profit Margin 91.64%
Selling, General & Admin $12.57M
YoY Change -15.44%
% of Gross Profit 160.64%
Research & Development $16.33M
YoY Change -30.97%
% of Gross Profit 208.69%
Depreciation & Amortization $134.0K
YoY Change -10.67%
% of Gross Profit 1.71%
Operating Expenses $28.91M
YoY Change -24.97%
Operating Profit -$21.08M
YoY Change -33.39%
Interest Expense -$3.245M
YoY Change -176.5%
% of Operating Profit
Other Income/Expense, Net $100.0K
YoY Change -90.21%
Pretax Income -$24.23M
YoY Change -26.53%
Income Tax
% Of Pretax Income
Net Earnings -$24.23M
YoY Change -26.53%
Net Earnings / Revenue -283.63%
Basic Earnings Per Share -$0.42
Diluted Earnings Per Share -$0.42
COMMON SHARES
Basic Shares Outstanding 55.19M 55.08M
Diluted Shares Outstanding 57.23M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.18M
YoY Change -76.08%
Cash & Equivalents $42.20M
Short-Term Investments
Other Short-Term Assets $4.660M
YoY Change -60.17%
Inventory $6.717M
Prepaid Expenses
Receivables $3.840M
Other Receivables $0.00
Total Short-Term Assets $57.40M
YoY Change -70.57%
LONG-TERM ASSETS
Property, Plant & Equipment $4.882M
YoY Change 24.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.341M
YoY Change -27.79%
Total Long-Term Assets $6.223M
YoY Change 7.93%
TOTAL ASSETS
Total Short-Term Assets $57.40M
Total Long-Term Assets $6.223M
Total Assets $63.62M
YoY Change -68.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.707M
YoY Change 41.17%
Accrued Expenses $14.16M
YoY Change -22.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $13.48M
YoY Change 75.0%
Total Short-Term Liabilities $34.50M
YoY Change 12.92%
LONG-TERM LIABILITIES
Long-Term Debt $41.71M
YoY Change -35.63%
Other Long-Term Liabilities $54.15M
YoY Change 6.38%
Total Long-Term Liabilities $95.86M
YoY Change -17.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.50M
Total Long-Term Liabilities $95.86M
Total Liabilities $130.4M
YoY Change -10.87%
SHAREHOLDERS EQUITY
Retained Earnings -$670.6M
YoY Change 26.48%
Common Stock $55.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$66.74M
YoY Change
Total Liabilities & Shareholders Equity $63.62M
YoY Change -68.32%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$24.23M
YoY Change -26.53%
Depreciation, Depletion And Amortization $134.0K
YoY Change -10.67%
Cash From Operating Activities -$19.45M
YoY Change -22.71%
INVESTING ACTIVITIES
Capital Expenditures $1.114M
YoY Change 1137.78%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$1.114M
YoY Change -109.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.925M
YoY Change -107.43%
NET CHANGE
Cash From Operating Activities -19.45M
Cash From Investing Activities -1.114M
Cash From Financing Activities -1.925M
Net Change In Cash -22.49M
YoY Change -277.66%
FREE CASH FLOW
Cash From Operating Activities -$19.45M
Capital Expenditures $1.114M
Free Cash Flow -$20.57M
YoY Change -18.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 mrns Revenue Interest Financing Agreement Issuance Costs
RevenueInterestFinancingAgreementIssuanceCosts
100000
mrns Revenue Interest Financing Agreement Estimated Effective Annual Interest Rate
RevenueInterestFinancingAgreementEstimatedEffectiveAnnualInterestRate
0.17
CY2022Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
30877000
mrns Revenue Interest Financing Agreement Non Cash Interest Income Expense
RevenueInterestFinancingAgreementNonCashInterestIncomeExpense
4421000
mrns Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
194000
mrns Revenue Interest Financing Agreement Payments
RevenueInterestFinancingAgreementPayments
-736000
CY2023Q3 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
34756000
CY2023Q3 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
1901000
CY2023Q3 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
32855000
CY2023Q3 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
34756000
CY2023Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
35977000
mrns Revenue Interest Financing Agreement Non Cash Interest Income Expense
RevenueInterestFinancingAgreementNonCashInterestIncomeExpense
4528000
mrns Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
441000
mrns Revenue Interest Financing Agreement Payments
RevenueInterestFinancingAgreementPayments
-1744000
CY2024Q3 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
39202000
CY2024Q3 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
3163000
CY2024Q3 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
36039000
CY2024Q3 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
39202000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
400000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
500000
CY2024Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.20
us-gaap Restructuring Charges
RestructuringCharges
2000000.0
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
us-gaap Payments For Restructuring
PaymentsForRestructuring
1622000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
330000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesNoncurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001267813
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesNoncurrent
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36576
dei Entity Registrant Name
EntityRegistrantName
MARINUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0198082
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Radnor Corporate Center, Suite 500
dei Entity Address Address Line2
EntityAddressAddressLine2
100 Matsonford Rd
dei Entity Address City Or Town
EntityAddressCityOrTown
Radnor
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19087
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
801-4670
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MRNS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55185622
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42184000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120572000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
29716000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3840000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3799000
CY2024Q3 us-gaap Inventory Net
InventoryNet
6717000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2413000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4660000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8746000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
57401000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
165246000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4882000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3843000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1341000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1819000
CY2024Q3 us-gaap Assets
Assets
63624000
CY2023Q4 us-gaap Assets
Assets
170908000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3707000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4003000
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
13475000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
11551000
CY2024Q3 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
3163000
CY2023Q4 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
2211000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14159000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22859000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
34504000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40624000
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
41713000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
61423000
CY2024Q3 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
36039000
CY2023Q4 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
33766000
CY2024Q3 mrns Contract With Customer Contract Liability Net Of Contract Asset
ContractWithCustomerContractLiabilityNetOfContractAsset
18108000
CY2023Q4 mrns Contract With Customer Contract Liability Net Of Contract Asset
ContractWithCustomerContractLiabilityNetOfContractAsset
17545000
CY2023Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
785000
CY2024Q3 us-gaap Liabilities
Liabilities
130364000
CY2023Q4 us-gaap Liabilities
Liabilities
154143000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55192929
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55185622
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54585428
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54578121
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
55000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
55000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
603853000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
588656000
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7307
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7307
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-670648000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-571926000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-66740000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16765000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63624000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170908000
CY2024Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
56000
CY2023Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1891000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
295000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
10753000
CY2024Q3 us-gaap Revenues
Revenues
8541000
CY2023Q3 us-gaap Revenues
Revenues
7338000
us-gaap Revenues
Revenues
24276000
us-gaap Revenues
Revenues
23799000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16334000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23661000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61349000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73006000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12573000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14868000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47909000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45794000
us-gaap Restructuring Charges
RestructuringCharges
1950000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
29621000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
38984000
us-gaap Costs And Expenses
CostsAndExpenses
113413000
us-gaap Costs And Expenses
CostsAndExpenses
119847000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21080000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31646000
us-gaap Operating Income Loss
OperatingIncomeLoss
-89137000
us-gaap Operating Income Loss
OperatingIncomeLoss
-96048000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
598000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1895000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3169000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6366000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3843000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4242000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12806000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
12597000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
100000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1021000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1105000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24225000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32972000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-98722000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101174000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1538000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24225000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32972000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-98722000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-99636000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57229229
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57229229
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53920109
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53920109
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57049038
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57049038
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52755114
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52755114
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
43000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
20000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-71000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24225000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32929000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98702000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-99707000
us-gaap Profit Loss
ProfitLoss
-98722000
us-gaap Profit Loss
ProfitLoss
-99636000
us-gaap Depreciation
Depreciation
405000
us-gaap Depreciation
Depreciation
426000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2278000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1659000
mrns Accretion Of Revenue Interest Financing Debt
AccretionOfRevenueInterestFinancingDebt
2784000
mrns Accretion Of Revenue Interest Financing Debt
AccretionOfRevenueInterestFinancingDebt
4421000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
149000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
995000
us-gaap Share Based Compensation
ShareBasedCompensation
14940000
us-gaap Share Based Compensation
ShareBasedCompensation
11638000
mrns Increase Decrease Amortization Of Net Contract Asset Liability
IncreaseDecreaseAmortizationOfNetContractAssetLiability
1018000
mrns Increase Decrease Amortization Of Net Contract Asset Liability
IncreaseDecreaseAmortizationOfNetContractAssetLiability
1259000
mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
112000
mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
146000
mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
567000
mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
300000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
61000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
757000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-1581000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-2079000
mrns Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable
1174000
mrns Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable
6290000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-10116000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3559000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87755000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91009000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
29885000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
17000000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
51995000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1152000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
85000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28733000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35071000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
257000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
783000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
19623000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-737000
mrns Proceeds From Equity Offerings Net
ProceedsFromEquityOfferingsNet
25920000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-19366000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25966000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-78388000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-100114000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120572000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
240551000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42184000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140437000
mrns Unrealized Gain Loss On Short Term Investments Cash Flow
UnrealizedGainLossOnShortTermInvestmentsCashFlow
20000
mrns Unrealized Gain Loss On Short Term Investments Cash Flow
UnrealizedGainLossOnShortTermInvestmentsCashFlow
-71000
mrns Financing Costs
FinancingCosts
97000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
221000
us-gaap Interest Paid Net
InterestPaidNet
7944000
us-gaap Interest Paid Net
InterestPaidNet
6540000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
903000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
116000000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3741000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
74000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34730000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
85085000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3891000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
485000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-188000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31934000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
57339000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4006000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
298000
CY2023Q3 us-gaap Share Price
SharePrice
7.17
CY2023Q3 mrns Stock Issuance Costs
StockIssuanceCosts
529000
CY2023Q3 mrns Stock Issued During Period Value Equity Distribution Agreement
StockIssuedDuringPeriodValueEquityDistributionAgreement
25823000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
43000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-32972000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
54537000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16765000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5193000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
20000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-38669000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-16434000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4917000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-35828000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-47345000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4830000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-24225000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-66740000
us-gaap Net Income Loss
NetIncomeLoss
-98700000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-670600000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p>
mrns Number Of Customers
NumberOfCustomers
3
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
mrns Number Of Customers
NumberOfCustomers
3
mrns Trade Receivable Payment Term
TradeReceivablePaymentTerm
P30D
CY2024Q3 us-gaap Cash
Cash
1100000
CY2024Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
41100000
CY2023Q4 us-gaap Cash
Cash
1300000
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
119300000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
200000
CY2024Q3 us-gaap Interest Receivable
InterestReceivable
0
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29736000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
169000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
189000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29716000
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
4806000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
436000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1560000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1075000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
351000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
902000
CY2024Q3 us-gaap Inventory Net
InventoryNet
6717000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2413000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2129000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7746000
CY2024Q3 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
3867000
CY2023Q4 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
4701000
CY2023Q4 mrns Accrued License Agreement Payment
AccruedLicenseAgreementPayment
4000000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
858000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1236000
CY2024Q3 mrns Selling And Commercial Liabilities Current
SellingAndCommercialLiabilitiesCurrent
6106000
CY2023Q4 mrns Selling And Commercial Liabilities Current
SellingAndCommercialLiabilitiesCurrent
3901000
CY2024Q3 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
804000
CY2023Q4 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
774000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
395000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
501000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14159000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22859000
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10565340
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8453977
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4830000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4006000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14940000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11638000
CY2022Q4 mrns Maximum Percentage Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.0999
CY2022Q4 mrns Maximum Percentage Increase Or Decrease Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageIncreaseOrDecreaseOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.1999
CY2022Q4 mrns Number Of Days Prior Notice To Increase Or Decrease Beneficial Interest Threshold Limit
NumberOfDaysPriorNoticeToIncreaseOrDecreaseBeneficialInterestThresholdLimit
P61D
CY2020Q3 mrns Maximum Shares Available For Issuance Value Equity Distribution Agreement
MaximumSharesAvailableForIssuanceValueEquityDistributionAgreement
75000000
mrns Equity Distribution Agreement Commission Percentage Maximum
EquityDistributionAgreementCommissionPercentageMaximum
0.030
mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
CY2023Q3 mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
CY2024Q3 mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
CY2024Q3 mrns Maximum Shares Available For Issuance Value Equity Distribution Agreement
MaximumSharesAvailableForIssuanceValueEquityDistributionAgreement
48600000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
500000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1000000.0
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
800000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1400000
us-gaap Lease Cost
LeaseCost
1400000
us-gaap Lease Cost
LeaseCost
400000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
800000
CY2023Q3 us-gaap Lease Cost
LeaseCost
100000
CY2024Q3 us-gaap Lease Cost
LeaseCost
100000
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.110
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
800000
CY2024Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
211000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
642000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
853000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
49000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
804000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
804000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
804000
CY2024Q3 mrns Debt Instrument Principal Payments Reduction Percentage
DebtInstrumentPrincipalPaymentsReductionPercentage
0.50
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
58100000
CY2024Q3 mrns Debt Instrument Minimum Liquidity Covenant
DebtInstrumentMinimumLiquidityCovenant
15000000.0
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000
CY2024Q3 mrns Contractual Term Loan Exit Fees
ContractualTermLoanExitFees
2003000
CY2024Q3 mrns Debt Instrument Principal Payment Including Associated Exit Fee
DebtInstrumentPrincipalPaymentIncludingAssociatedExitFee
19251000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2564000
CY2024Q3 us-gaap Notes Payable
NotesPayable
55188000
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
13475000
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
41713000
CY2024Q3 us-gaap Notes Payable
NotesPayable
55188000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1875000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
15000000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
39375000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
56250000
mrns Revenue Interest Financing Agreement Issuance Costs
RevenueInterestFinancingAgreementIssuanceCosts
2600000

Files In Submission

Name View Source Status
0001558370-24-015315-index-headers.html Edgar Link pending
0001558370-24-015315-index.html Edgar Link pending
0001558370-24-015315.txt Edgar Link pending
0001558370-24-015315-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrns-20240930.xsd Edgar Link pending
mrns-20240930x10q.htm Edgar Link pending
mrns-20240930x10q004.jpg Edgar Link pending
mrns-20240930xex31d1.htm Edgar Link pending
mrns-20240930xex31d2.htm Edgar Link pending
mrns-20240930xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
mrns-20240930_cal.xml Edgar Link unprocessable
mrns-20240930_def.xml Edgar Link unprocessable
mrns-20240930_lab.xml Edgar Link unprocessable
mrns-20240930_pre.xml Edgar Link unprocessable
mrns-20240930x10q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable